Regardless of QLQ-C30 or EQ-5D-3L, the results of the meta-analysis suggested that NSCLC patients with PD-1/PD-L1 inhibitors had a more favorable difference in mean change from baseline to follow-up compared to those with chemotherapy and had a significantly delayed clinical deterioration. Here, PDCD1 is linked to non-small cell lung carcinoma.